Literature DB >> 33552068

Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment.

Yang Zhang1, Yanni Lou2, Jingbin Wang3, Cunguo Yu4, Wenjuan Shen5.   

Abstract

Treatment of malignant tumors encompasses multidisciplinary comprehensive diagnosis and treatment and reasonable combination and arrangement of multidisciplinary treatment, which is not a simple superimposition of multiple treatment methods, but a comprehensive consideration of the characteristics and specific conditions of the patients and the tumor. The mechanism of tumor elimination by restoring the body's immune ability is consistent with the concept of "nourishing positive accumulation and eliminating cancer by itself" in traditional Chinese medicine (TCM). The formation and dynamic changes in the tumor microenvironment (TME) involve many different types of cells and multiple signaling pathways. Those changes are similar to the multitarget and bidirectional regulation of immunity by TCM. Discussing the relationship and mutual influence of TCM and antitumor therapy on the TME is a current research hotspot. TCM has been applied in the treatment of more than 70% of cancer patients in China. Data have shown that TCM can significantly enhance the sensitivity to chemotherapeutic drugs, enhance tumor-suppressing effects, and significantly improve cancer-related fatigue, bone marrow suppression, and other adverse reactions. TCM treatments include the application of Chinese medicine monomers, extracts, classic traditional compound prescriptions, listed compound drugs, self-made compound prescriptions, as well as acupuncture and moxibustion. Studies have shown that the TCM functional mechanism related to the positive regulation of cytotoxic T cells, natural killer cells, dendritic cells, and interleukin-12, while negatively regulating of regulatory T cells, tumor-associated macrophages, myeloid-derived suppressive cells, PD-1/PD-L1, and other immune regulatory factors. However, the application of TCM in cancer therapy needs further study and confirmation. This article summarizes the existing research on the molecular mechanism of TCM regulation of the TME and provides a theoretical basis for further screening of the predominant population. Moreover, it predicts the effects of the combination of TCM and antitumor therapy and proposes further developments in clinical practice to optimize the combined strategy.
Copyright © 2021 Zhang, Lou, Wang, Yu and Shen.

Entities:  

Keywords:  anti-tumor therapy; cancer; immune ability; traditional Chinese medicine; tumor microenvironment

Year:  2021        PMID: 33552068      PMCID: PMC7859437          DOI: 10.3389/fimmu.2020.609705

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  69 in total

Review 1.  The global cancer burden and human development: A review.

Authors:  Miranda M Fidler; Freddie Bray; Isabelle Soerjomataram
Journal:  Scand J Public Health       Date:  2017-07-01       Impact factor: 3.021

Review 2.  The Tumor Microenvironment Innately Modulates Cancer Progression.

Authors:  Dominique C Hinshaw; Lalita A Shevde
Journal:  Cancer Res       Date:  2019-07-26       Impact factor: 12.701

Review 3.  Opportunities and challenges of radiotherapy for treating cancer.

Authors:  Dörthe Schaue; William H McBride
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

4.  Fear of cancer recurrence: A qualitative systematic review and meta-synthesis of patients' experiences.

Authors:  Susana N Almeida; Robert Elliott; Eunice R Silva; Célia M D Sales
Journal:  Clin Psychol Rev       Date:  2018-12-21

Review 5.  Evaluation of Traditional Chinese Medicine Herbs in Oncology Clinical Trials.

Authors:  Jie Liu; Jun J Mao; Xin Shelley Wang; Hongsheng Lin
Journal:  Cancer J       Date:  2019 Sep/Oct       Impact factor: 3.360

Review 6.  The multi-factorial nature of clinical multidrug resistance in cancer.

Authors:  Yehuda G Assaraf; Anamaria Brozovic; Ana Cristina Gonçalves; Dana Jurkovicova; Aija Linē; Miguel Machuqueiro; Simona Saponara; Ana Bela Sarmento-Ribeiro; Cristina P R Xavier; M Helena Vasconcelos
Journal:  Drug Resist Updat       Date:  2019-09-17       Impact factor: 18.500

7.  Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cells.

Authors:  Shun Takaku; Masumi Shimizu; Hidemi Takahashi
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

8.  The Chinese medicine JC-001 enhances the chemosensitivity of Lewis lung tumors to cisplatin by modulating the immune response.

Authors:  Meng-Hsien Chuang; Ming-Shiou Jan; Jinghua Tsai Chang; Fung-Jou Lu
Journal:  BMC Complement Altern Med       Date:  2017-04-11       Impact factor: 3.659

9.  Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment.

Authors:  Ji Lv; Yitao Jia; Jing Li; Wentao Kuai; Yang Li; Fang Guo; Xinjian Xu; Zhaolong Zhao; Jian Lv; Zhongxin Li
Journal:  Cell Death Dis       Date:  2019-05-28       Impact factor: 8.469

10.  PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.

Authors:  Wing Lam; Zaoli Jiang; Fulan Guan; Xiu Huang; Rong Hu; Jing Wang; Scott Bussom; Shwu-Huey Liu; Hongyu Zhao; Yun Yen; Yung-Chi Cheng
Journal:  Sci Rep       Date:  2015-03-30       Impact factor: 4.996

View more
  13 in total

1.  Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.

Authors:  Jia-Li Wang; Chuan-Sheng Chen; Zhi-Rong Jia; Li-Yun Miao; Jun Xie; Zhen-Zhen Pan; Ya-Lei Duan; Shuo Liu; Meng-Jun Hou; Xuan-Sheng Ding
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-26       Impact factor: 4.322

2.  Neferine, a novel ROCK1-targeting inhibitor, blocks EMT process and induces apoptosis in non-small cell lung cancer.

Authors:  Po Hu; Peng Wan; Anna Xu; Binghui Yan; Chunmei Liu; Qixuan Xu; Zhenhuan Wei; Jingyi Xu; Siqi Liu; Guangming Yang; Yang Pan
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-19       Impact factor: 4.322

3.  Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime.

Authors:  Canjing Zhang; Huiwen Xu; Xianxian Sui; Lina Chen; Bobin Chen; Haozhen Lv; Songmei Wang; Xuanyi Wang
Journal:  Mol Ther Oncolytics       Date:  2022-05-04       Impact factor: 6.311

Review 4.  Role of immune escape in different digestive tumours.

Authors:  Xin-Zhu Du; Bin Wen; Lin Liu; Ying-Ting Wei; Kui Zhao
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

5.  A redox-responsive dihydroartemisinin dimeric nanoprodrug for enhanced antitumor activity.

Authors:  Yawei Li; Qing Pei; Baiji Cui; Hongmei Zhang; Liu Han; Wenqing Li; Wenhe Zhu; Xianmin Feng; Zhigang Xie
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

6.  Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer.

Authors:  Jie Hou; Ke Shi; Yao Liu; Jialiang Chen; Chongping Ran; Xianbo Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-17       Impact factor: 2.629

7.  The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Juan Wang; Xu Han; Ye Yuan; Hao Gu; Xing Liao; Miao Jiang
Journal:  Front Genet       Date:  2022-04-05       Impact factor: 4.772

Review 8.  Therapeutics for Chemotherapy-Induced Peripheral Neuropathy: Approaches with Natural Compounds from Traditional Eastern Medicine.

Authors:  Geehoon Chung; Sun Kwang Kim
Journal:  Pharmaceutics       Date:  2022-07-05       Impact factor: 6.525

9.  The Regulating Effect of CII-3 and Its Active Components from Periplaneta americana on M1/M2 Macrophage Polarization.

Authors:  Jinglei Xu; Yihao Che; Xinyue Liu; Chaohe Liu; Di Meng; Xiuqin Pang; Miao He; Guangming Liu; Chenggui Zhang; Dasong Yang; Huai Xiao
Journal:  Molecules       Date:  2022-07-10       Impact factor: 4.927

Review 10.  Bioactive constituents of animal-derived traditional Chinese medicinal materials for breast cancer: opportunities and challenges.

Authors:  Chaochao Yu; Yi Li; Guopeng Chen; Chaoyan Wu; Xiuping Wang; Yingwen Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2022-07-15       Impact factor: 5.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.